289
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study

, , , , , , , , , , & show all
Pages 838-845 | Received 02 Jun 2014, Accepted 15 Jul 2014, Published online: 17 Sep 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Tae Eun Park, Abdilahi Mohamed, Julie Kalabalik & Roopali Sharma. (2015) Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Review of Anti-infective Therapy 13:10, pages 1195-1212.
Read now
Andrea Calcagno, Antonio D’Avolio & Stefano Bonora. (2015) Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients. Expert Opinion on Drug Metabolism & Toxicology 11:7, pages 1167-1176.
Read now

Articles from other publishers (5)

Gabriele Arendt, Svenja Schlonies, Eser Orhan & Olaf Stüve. (2019) Simplification of combination antiretroviral therapy (cART) and the brain—a real-life experience. Journal of NeuroVirology 25:2, pages 174-182.
Crossref
Maria José Rolón, Omar Sued & Pedro Cahn. (2017) Simplifying HAART: the Role of Two-Drug Therapy. Current Treatment Options in Infectious Diseases 9:2, pages 250-261.
Crossref
. (2015) Atazanavir/raltegravir. Reactions Weekly 1572:1, pages 34-34.
Crossref
Jacques Leibowitch, Dominique Mathez, Pierre Truchis, Damien Ledu, Jean Claude Melchior, Guislaine Carcelain, Jacques Izopet, Christian Perronne & John R. David. (2015) Four days a week or less on appropriate anti‐HIV drug combinations provided long‐term optimal maintenance in 94 patients: the ICCARRE project. The FASEB Journal 29:6, pages 2223-2234.
Crossref
Sreekumar Othumpangat, John D. Noti & Sidhartha D Ray. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions 329 348 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.